Obtain AST/ALT, hepatitis B envelope antigen, hepatitis B surface antigen, HBV DNA levels every 3 months for the 1 year of therapy and annually thereafter during treatment. Following treatment discontinuation monitor every 3 months for 1 year then annually thereafter.
Monitor hepatitis B screening at baseline and with modification of ARV treatment.
Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.
Monitor viral load prior to initiation or modification of treatment.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.